Model coronavirus stock BioNTech ((NASDAQ: (BNTX))) shot 6.6% higher Friday. This was due to encouraging news about the coronavirus vaccine BNT162b2, which it developed with Pfizer (NYSE: PFE). A big pronouncement by a major health authority also helped.
In a 175-participant study of elderly patients who had received both doses of the two-jab BNT162b2, British researchers found that it actually induces a stronger antibody response when the two shots are spaced further apart than recommended — 12 weeks rather than the three of official guidance.
Image source: Getty Images.
The UK. scientists found that when the gap was widened to 12 weeks, the study’s participants experienced antibody responses that were 3.5 times higher than those of the three-weekers.
While more work certainly needs to be done on this phenomenon, it’s yet another indication that the vaccine is highly effective. As such, it’ll remain a leading go-to solution for beating back the coronavirus pandemic.
Compounding that positive development, the U.S. Centers for Disease Control and Prevention (CDC) Thursday updated guidance for fully vaccinated individuals. The CDC now advises that such people can participate in a wide range of activities without wearing a mask.
The CDC’s update is less obviously beneficial for BioNTech than the study’s findings. It’s very possible that those previously reluctant to get their shots will do so with the inducement of eventually being able to go maskless. Combined, these developments point to a strong and sustained future for the biotech and its key product.
10 stocks we like better than BioNTech SE
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Fintech Zoom Stock Advisor, has tripled the market.*
David and Tom just revealed what they believe are the ten best stocks for investors to buy right now… and BioNTech SE wasn’t one of them! That’s right — they think these 10 stocks are even better buys.
See the 10 stocks
*Stock Advisor returns as of May 11, 2021
Eric Volkman has no position in any of the stocks mentioned. The Fintech Zoom has no position in any of the stocks mentioned. The Fintech Zoom has a disclosure policy.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.